UPDATE: Stifel Nicolaus Raises PT on InterMune Awaiting Inflection Point
In a report published Thursday, Stifel Nicolaus analyst Stephen Willey reiterated a Buy rating on InterMune (NASDAQ: ITMN), and raised the price target from $17.00 to $18.00.
In the report, Stifel Nicolaus noted, “We believe 4Q13 now likely represents the long-awaited inflection point investors have been waiting to materialize in the model. However, we note the realization of that upside now increasingly looks like it will coincide with the disclosure of a competitive P3 data point from BI's nintedanib. And, while our recent review of nintedanib safety/tolerability data from ASCO would suggest Esbriet may have an advantage here, we note the introduction of another more-conveniently dosed agent of even equivalent/modest efficacy could limit visibility into a disease setting where a lack of definable progression makes it challenging for physicians to sequence therapy. However, we still find valuation and optionally around ASCEND data attractive here and remain Buy-rated.”
InterMune closed on Wednesday at $12.81.
Latest Ratings for ITMN
|Aug 2014||Cowen & Company||Initiates Coverage on||Market Perform|
|Aug 2014||JMP Securities||Downgrades||Market Outperform||Market Perform|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.